Tag: therapeutic proteins

Sanofi’s SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration

PARIS, July 07, 2025 (GLOBE NEWSWIRE) --  PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to announce that the first patient has been successfully dosed in its Phase I clinical trial (PST-611-CT1) aiming to assess safety and tolerability of its lead program, PST-611, in humans.

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry.

The Protein Drugs Market, valued at USD 441.7 billion in 2024, is set to reach USD 655.7 billion by 2029, growing at an 8.2% CAGR. The report covers market trends, technologies, regional insights, and company profiles, highlighting the rise of recombinant protein drugs for treating diseases like cancer and diabetes.